Core Viewpoint - The company has received official registration approval from the National Medical Products Administration of China for its G-BranchTM thoracoabdominal aortic stent graft system, developed in collaboration with a team from the First Medical Center of the Chinese People's Liberation Army General Hospital, marking a significant advancement in the treatment of thoracoabdominal aortic aneurysms (TAAA) [1][2] Group 1 - The G-BranchTM system is designed for the treatment of TAAA involving the celiac trunk, superior mesenteric artery, and bilateral renal arteries, enabling complete endovascular reconstruction of the thoracoabdominal aorta [1] - The product features a world-first "dual inner and dual outer flip" hybrid branch design, with different diameters for the upper and lower segments of the stent body, aligning with the starting positions of the body's visceral branch vessels [1] - The company holds independent intellectual property rights for the G-BranchTM product, which is expected to provide a systemic solution for TAAA patients through a fully endovascular approach, promising less trauma, simpler operation, and better adaptability [1] Group 2 - Following the approval of the aortic arch stent system and aortic covered stent system in the first half of 2025, the G-BranchTM product further enriches the company's product portfolio in the peripheral vascular intervention field [2] - The company is positioned as a leading innovative enterprise globally with a complete endovascular repair solution for the aorta, enhancing its commercial offerings [2] - The ongoing commercialization process aims to provide more flexible, comprehensive, safe, effective, and easy-to-operate solutions for thoracoabdominal aortic aneurysm reconstruction, while collaborating with industry experts to advance the development and launch of urgently needed medical devices [2]
先健科技(01302)：G-BranchTM胸腹主动脉覆膜支架系统获得国家药品监督管理局的正式注册批准